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INTRODUCTION
Histoplasmosis, blastomycosis, and coccidioidomycosis are the three major
endemic fungi in North America. Although histoplasmosis is found in all
continents except Antarctica, coccidioidomycosis in South America, and
blastomycosis in Africa, only in North America are these illnesses
common.
These three fungal diseases share many characteristics. The causative
agents are mycelial soil organisms. Illness is acquired by inhaling
aerosolized spores. In the infected host, the organisms change their form, a
characteristic called dimorphism. Histoplasma capsulatum and
Blastomyces dermatitidis convert to a yeast form at 37 degrees C (thermal
dimorphism), whereas Coccidioides immitis converts in tissue to a spherule
that replicates by forming endospores (tissue dimorphism).
The endemic areas are large. Most of the Midwest and South Central
United States is endemic for both histoplasmosis [1] and blastomycosis
[2], and a large area in the Southwest United States and an adjacent area of
Mexico are endemic for coccidioidomycosis [3]. All three illnesses occur in
normal hosts, although histoplasmosis and coccidioidomycosis are also
major opportunistic mycoses in patients with depressed cell-mediated
immunity, and especially in patients with acquired immunodeficiency
syndrome (AIDS) [4],[5].
Histoplasmosis, blastomycosis and coccidioidomycosis are major T-cell
opportunistic infections, as demonstrated by the very aggressive course
seen in patients with AIDS, in whom T-cell deficiency is most severe.
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HISTOPLASMOSIS
In the United States H. capsulatum var. capsulatum is responsible for the
majority of the cases of histoplasmosis. H. capsulatum var. duboisii is
predominantly found in south Africa and Europe (6). The spectrum of
disease ranges from the asymptomatic acquisition of a positive
histoplasmin skin test reaction to a rapidly fatal pulmonary or disseminated
illness. It is the balance between the net immune status of the subject and
the load of the infecting inoculum that determines the severity of the illness.
During the past two decades, histoplasmosis has emerged as a common
opportunistic infection in patients with AIDS especially those residing in
endemic areas. Most of our current knowledge about this disease is derived
from outbreak investigation in the Midwestern United States.
The Pathogen and Epidemiology
Histoplasma is a thermally dimorphic fungus. It has two forms; a mycelia
phase and a yeast phase. Mycelia are the forms found in the environment,
they are considered to be the infectious form. Mycelia display macro-and
micro-conidia. Yeasts are what are found in the infected individuals. In the
laboratory these two forms are inter-convertible by altering the
temperatures and nutrients of the growth medium. The disease is highly
endemic in the Midwestern and southeastern parts of the US. It is estimated
that 50-80% of people living in the Ohio and Mississippi river valleys have
evidence of remote infection with histoplasma [7]
Human and animal infections occurred after inhalation of aerosolized
micro-conidia, the infecting particle, which can reach the alveolar space
due to its very small size of 2 to 5 mm. Extensive skin test surveys suggest
that as many as 50 million people in the United States have been infected
by H. capsulatum and that there are up to 500,000 new infections yearly
[8].
For decades most outbreaks have occurred in urban settings. Most are
associated with construction projects that disturbed contaminated soil. The
most recent (and largest ever) outbreak occurred in Indianapolis, Indiana
[9], associated with downtown construction of a swimming pool complex.
Endemic mycosis 197
Mini-outbreaks also still occur. Activities such as cutting up fallen trees or
cleaning large bushes have been linked to smaller outbreaks.
Histoplasmosis occurs in 2 to 5% of patients with AIDS who reside in
endemic areas and up to 25% in selected areas during periods of outbreaks
[10].
Pathogenesis. The lung is the portal of entry in almost every case. Due to
their small size, microconidia can reach the alveolar space where they
convert to the yeast form, a key step in the pathogenesis. The initial tissue
response to the organism is predominantly neutrophilic, followed by an
increase in alveolar macrophages [11]. After being phagocytosed, yeast
survive and actually proliferate inside the macrophages, which serve then
as a carrier throughout the reticuloendothelial system. Shortly after
infection the yeast forms can be identified in the mediastinal lymph nodes.
The fungus then gains access to the circulation. It is likely that transient
self-limited fungemia occurs in most, if not all, patients. Later the yeast
disseminates throughout the body to establish foci of infection in many
organs, such as the liver, spleen and the adrenal glands [5].
About two weeks after infection, specific cellular immunity begins to
develop. Activated lymphocytes secrete cytokines that stimulate
macrophages in an attempt to boost their fungicidal activity. In mice,
interleukin-12 is an important signal, leading to increased interferon-
gamma production that confers protection against primary infection [12],
[13], [14]. Tumor necrosis factor-alpha seems to be an important element
in this scheme. Inhibition of has been shown to alter the adaptive
immune response to histoplasma infection and may predispose patients
disseminated infection [12], [15], [16].
With the advent of T-lymphocyte-mediated cellular immunity, fungal
replication is checked and granuloma formation begins. Healing of these
lesions is accompanied by peripheral fibrosis. Central areas of
encapsulated, necrotic material frequently calcify. These calcified foci
manifest on chest roentgenogram as single or multiple calcified nodules.
Calcified lesions are often seen in the liver and the spleen [17].
If the cell-mediated immune response is poor, the yeast continues to
multiply. More macrophages are recruited, which in turn become
parasitized and eventually disrupted, perpetuating the cycle [5]. A severe
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systemic illness develops, which invariably leads to death unless treated
promptly and aggressively.
Clinical Manifestations. Most normal persons who are infected by the
fungus remain asymptomatic. When present, symptoms vary widely from
brief periods of malaise to severe, life-threatening illness. It is classically a
flu-like illness with abrupt onset of fever, chills, and substernal chest
discomfort. A harsh, nonproductive cough develops along with headache,
arthralgias, and myalgias.
In immunocompetent individuals severe pulmonary illness develops rarely,
only when the infective dose is unusually high. It may progress rapidly to
the acute respiratory distress syndrome, and may lead to death from
respiratory insufficiency if not treated promptly [1].
Immunocompromised individuals are more likely to progress to
disseminated disease even after an infection with a smaller inoculum. The
vast majority of progressive disseminated histoplasmosis is seen in patients
with advanced AIDS with CD4 counts below 200 cells/mL [10].
Progressive Disseminated Histoplasmosis
Most patients with progressive disseminated Histoplasmosis present with
fever, chills, weight loss, cough and progressive dyspnea [18]. On physical
examination, patients are febrile and acutely ill. Hepatosplenomegaly may
be present. Laboratory evaluation shows anemia, leukopenia, and
thrombocytopenia. In extremely ill patients the syndrome of disseminated
intravascular coagulation may be seen. Up to 20% of patients present with
severe septic shock, respiratory failure and progress to multi-organ failure.
This syndrome represents an advanced stage of the illness and is usually
seen when diagnosis and appropriate therapy were delayed. Mortality is
very high with this scenario.
The chest roentgenographic findings are variable, ranging from normal to
diffusely abnormal, with reticulonodular pattern being the most frequently
reported finding. Pleural effusions are rarely seen [19]. The radiographic
findings are very similar to those seen with Pneumocystis carinii
pneumonia [4] ( Figure 1).
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Figure 1
Chest X-ray of a HIV + patient with progress
disseminated Histoplasmosis.
Peripheral blood smear may show phagocytoses yeast in some of patients
with severe disease. Biopsy material from the bone marrow and other
involved tissue shows collections of macrophages full of intracellular yeast
or, in the most severe instances, widespread necrosis with large numbers of
organisms lying loose in the extracellular debris. There is little, if any,
evidence of granuloma formation [20] . Virtually all patients with this form
of the illness have some degree of T-cell defect. Before the modern era of
widespread use of cytotoxic agents and glucocorticoids, many patients had
underlying Hodgkin’s disease, a well-known example of naturally occurring
T-cell immune deficiency [5], [4].
The most severe form of progressive disseminated histoplasmosis (PDH)
occurs in patients with AIDS with profound T-cell dysfunction [21]. In
fact, most cases of PDH now occur in AIDS patients, and most occur in
highly endemic areas [22], [23]. Newer biological therapies for
Rheumatoid Arthritis and other auto-immune disorders have added a new
pool of immunosuppressed patients at risk for tuberculosis and also
histoplasmosis and other T-cell opportunistic fungal infections.
In most instances, exposure of an immunosuppressed person to an infected
aerosol is the antecedent event preceding PDH. In the recent large outbreak
in Indianapolis, most patients who were immunocompromised when they
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developed primary histoplasmosis progressed to PDH [23]. In particular,
patients with AIDS nearly always progressed to PDH [10].
In other cases, the onset of PDH is temporally related to intense
immunosuppression, most commonly progression of AIDS or therapy with
high doses of glucocorticoids. In some of these cases, reactivation of
dormant histoplasmosis may be the mechanism of infection [4]. Patients
with AIDS who develop PDH after long residence in New York City or
San Francisco are clear examples of such endogenous reactivation because
primary infections are never seen in these cities.
Some patients with PDH present with a subacute to chronic illness. They
may have a chronic wasting disease with anorexia, weight loss, and low-
grade fever. Mucosal and mucocutaneous junction ulcers may occur in the
mouth, oral pharynx, rectum, and glans penis. Adrenal involvement may
cause Addison’s disease [24]. Biopsy material from involved tissues shows
well-formed epithelioid granulomas, and only a diligent search will reveal
rare organisms. Demonstration of organisms almost always requires special
stains [5], [20]. The disease may be systemic or involve only one organ.
This more chronic form of PDH generally occurs in patients who are less
immunosuppressed than the patients who develop more fulminant PDH.
Central nervous system histoplasmosis is rare and may present as chronic
meningitis or intracranial histoplasmoma [25]. Endocarditis can also occur,
involving either the aortic or mitral valves. Vegetations are usually large,
and emboli are common. Endocarditis may occur on prosthetic or
previously normal valves. Recently, histoplasma involvement of abdominal
aortic aneurysms has been reported in a few patients with the chronic form
of PDH [26].
Diagnosis
The gold standard of diagnosis is culture of the fungus from biologic
material. Cultures are time consuming and one cannot wait for them in the
management of cases with severe PDH. Delay in diagnosis while awaiting
results of fungal cultures may lead to a fatal outcome in more severe cases
Isolation of H. capsulatum may occur within 1 week in a minority of
patients but usually takes several weeks.
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Serologic studies of Histoplasmosis are seldom useful in the management
of PDH. Positive serology does not predict development of PDH in patients
undergoing bone marrow transplantation [27]. The complement fixation
test is negative in up to 50% of patients with PDH. Immunodiffusion fails
to identify up to 50% of patients with acute histoplasmosis and usually
does not reach maximum positivity for 4 to 6 weeks after exposure [28].
Their main drawbacks are imperfect sensitivity and lack of timeliness.
Several weeks must pass before they become positive. By that time, most
patients have either recovered or have required other more invasive
methods of diagnosis because of rapidly worsening disease
There are two ways to make a rapid diagnosis of PDH, sampling and
examination of likely infected tissue with the use of special stains and the
use of the ultrasensitive assay for fungal antigens.
Mycologic Studies.  Bronchoscopy is an important diagnostic tool,
especially for PDH. Specimens obtained from bronchoscopy have a high
but poorly defined yield in severe primary histoplasmosis with progressive
ARDS and especially in PDH in AIDS, when diffuse infiltrates are one of
the clinical features. In highly selected series the diagnostic yield of
bronchoscopy for diagnosis of histoplasmosis in an endemic area is about
60% in patients with infiltrates [29]. In a strictly AIDS population in
Indianapolis, Indiana, fungal stains performed on bronchoalveolar lavage
fluid provided a rapid diagnosis in 70% of patients; diagnostic yield
increased to 89% when culture results were included. In that series, 22%
of patients had co-infections or alternative diagnoses that were detected by
BAL and would not have been detected if Histoplasma antigen testing had
been the sole diagnostic test [30]. Use of cytologic examination without
special fungal staining (silver, PAS) may explain the lower yield of BAL
reported in series from non-endemic areas [31]. It is likely best to do a
battery of stains including a silver stain. Although transbronchial biopsy
is not mandatory at the time of bronchoscopy and BAL, histopathology
does appear to enhance the diagnostic yield [31]. The fungus is difficult to
see on standard hematoxylin and eosin stains; special stains (usually a
silver stain) are needed. Special stains are particularly important when
well-formed granulomas are present because of the paucity of organisms in
such cases.
In patients with suspected PDH, sampling of the reticuloendothelial system
is often effective for diagnosis. Bone marrow biopsy is likely the best and
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safest method [20] . In heavily parasitized samples, a direct smear of the
bone marrow, stained with a supravital stain such as the Giemsa stain,
usually gives a rapid diagnosis (Figure 2). On permanent histologic
sections, the fungus is difficult to see on standard slides prepared with
hematoxylin and eosin stain. It is best to go directly to special stains,
usually one of several modifications of the silver stain or the PAS stain.
Figure 2
Intraphagocytic yeasts seen on a bone marrow aspirate.
Recently, the role of blood cultures in diagnosis of PDH has expanded. The
lysis-centrifugation system increases sensitivity. In AIDS patients with
PDH, the density of organisms is higher than in other immunosuppressed
patients, and blood cultures are particularly useful, yielding a diagnosis in
up to 90% of cases. In fact, in AIDS patients with PDH typical
intracellular organisms can be seen directly on peripheral blood smears
(buffy coat preparations) up to 50% of the time. Bronchoalveolar lavage
also has a very high yield, both by direct smear and by culture in AIDS
patients with high burden of organisms. Bronchoalveolar lavage offers the
additional advantage of ready diagnosis of other opportunistic infections
that are usually in the differential diagnosis, including P. carinii
pneumonia.
Antigen Detection. Another approach to diagnosis of fungal infections is
the use of the ultrasensitive assays for fungal antigens. This test is very
useful when the burden of the infection is high. Detection of the
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histoplasma antigen in body fluids permits rapid diagnosis of PDH. The
specificity of antigen detection is greater than 98%. There is, however,
known cross reactivity with the other endemic fungi such as African
histoplasmosis, blastomycosis, paracoccidioidomycosis, and Penicillium
marneffii infection [32]. Sensitivity is lower in patients who are
moderately immunosuppressed. However, the high density of organisms in
AIDS patients with PDH makes antigen testing extremely useful in that
setting.
Antigen testing is more sensitive on urine than serum. It is positive in either
urine or serum in up to 95% of patients with PDH complicating AIDS
[30]. Levels of histoplasma polysaccharide antigen in urine and serum also
are useful for following the course of treatment and for predicting relapses
[33], [34]. The test is done reliably in a single reference laboratory in
Indianapolis, which makes it a “send out” for many institutions.
Treatment
Severe cases of PDH in non-AIDS patients are best treated promptly and
aggressively with amphotericin B to a total dose of 40 mg/kg. Itraconazole
(400 mg/day in a single daily dose) can be used successfully for patients
with mild to moderate disease [35]. Sequential therapy for severely ill
patients with amphotericin B to clinical improvement followed by 6 months
of itraconazole is also being used but is not well studied.
AIDS patients are treated differently from other PDH cases. Relapse is
expected if treatment is stopped. All patients require induction therapy to
control symptoms and then maintenance therapy. Amphotericin B is used
initially for all moderately and severely ill patients. After clinical response,
treatment is changed to itraconazole (400 mg daily for 6 or more weeks,
then 200 mg daily until sustained recovery of the immune system) [36],
[37]. There is emerging data that support the discontinuation of
maintenance Itraconazole in patients with HIV who recover their immune
system [38].
Itraconazole can be used from onset for mild cases[39]. Other maintenance
strategies for those intolerant of itraconazole include weekly amphotericin
B infusions or fluconazole at doses of at least 400 mg/day. Ketoconazole
therapy is ineffective for maintenance therapy, and fluconazole even at high
daily doses (400 to 800 mg) is less effective than itraconazole [40]. In a
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recent double blind, randomized trial liposomal amphotericin B (L-AMB)
was somewhat more effective than AMB in both time of response and
survival, although the differences were not statistically significant [41]. In
this study both types of AMB were used for fourteen days before switching
to oral itraconazole therapy.
BLASTOMYCOSIS
Blastomycosis is an illness caused by the thermal dimorphic fungus
Blastomyces dermatitidis. The spectrum of disease ranges from the
asymptomatic acquisition of the fungus to a rapidly progressive and life-
threatening respiratory or disseminated illness.
Epidemiology
Blastomycosis is most common in the central and south-central United
States [42]. The proposed endemic area includes much of the central, south
central, and southeastern United States, beginning near the Minnesota–
North Dakota border and extending eastward and southward. The
southeastern limit extends to South Carolina but not to Florida. This area
overlaps most of the endemic area of histoplasmosis [1]. The northern
limit, however, extends further. Northern Minnesota and northern
Wisconsin and also the adjacent Canadian provinces of Ontario and
Manitoba are endemic for blastomycosis but are free of histoplasmosis
[43], [44] .
Similar to H. capsulatum, B. dermatitidis is a soil-dwelling fungus.
Infection occurs by inhalation of airborne spores. Infected individuals
develop a positive blastomycin skin test reaction or the in vitro correlate of
delayed hypersensitivity. As with histoplasmosis, isolated microfoci of high
infectivity exist in a large endemic area. Outbreaks often occur during
activities such as hunting, camping, or canoeing in wooded or swampy
environments [45]; these are most common when soil temperatures have
been increasing for several days and when there is rain on the day of
exposure. For sporadic cases, residence close to water in a highly endemic
area and recent excavation activity are risk factors [46]. Dogs are also
susceptible to blastomycosis. Canine blastomycosis is a well-recognized
entity in veterinary practice in the endemic areas. The recognition of canine
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cases in a community should alert physicians that human blastomycosis
may be present in their geographic area [47].
Pathogenesis
At ambient temperatures, the fungus grows as an aerial mycelium. When
foci of actively growing blastomyces are disturbed, small 2- to spores
become airborne and an infective aerosol is formed. These infecting
particles then may be inhaled by humans or by other mammals disturbing
the site. Some spores may escape the nonspecific defenses of the lung and
reach the alveoli.
The initial inflammatory response is neutrophilic. As the organism converts
to the parasitic yeast form and begins to multiply, large numbers of yeast
are seen, surrounded by neutrophils. Following this macrophages increase
in number. Eventually, as specific cellular immunity develops, there are
giant cells and well-formed epithelioid granulomas. In contrast to
histoplasmosis, the neutrophilic component of the inflammatory response
does not disappear completely, and the histopathologic examination often
shows a mixed pyogenic and granulomatous response, even in chronic
cases [2].
It would be misleading, however, to think that there is a “characteristic”
tissue response in blastomycosis. Occasionally, the neutrophilic component
is minimal and the granulomas are noncaseating, producing a picture
similar to that of sarcoidosis. In contrast, granulomas are sometimes
entirely absent in overwhelming infections. The entire inflammatory
reaction consists of neutrophils, and the histopathologic picture mimics that
of bacterial infection.
The histopathologic response in cutaneous blastomycosis is striking. The
stratified squamous epithelium becomes markedly hyperplastic, with
exaggerated downgrowth of the rate pegs. Within these fingerlike
projections are a number of microabscesses. The same hypertrophic tissue
response is seen when the disease involves the oropharynx or the larynx.
The histopathologic appearance may superficially resemble carcinoma. The
characteristic organisms, seen best with special stains, provide a diagnosis.
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The initial inflammatory and immune response may confine the infection to
the lungs and the hilar lymph nodes. It is likely (but not proven) that self-
limited early fungemia does not occur as often as it does in histoplasmosis.
In some instances, however, the organism spreads beyond lung and the
hilar nodes. Dissemination is usually to skin, bones, prostate, and meninges
but can be seen in any organ [2], [48] .
The incubation time for blastomycosis is longer than for histoplasmosis and
more variable. In the Eagle River outbreak, in which time of exposure was
short and precisely defined, the median incubation period was 45 days,
with a range of 21 to 106 days [49], [50].
Clinical Manifestations
The portal of entry is almost always the lung, and the primary illness is a
lower respiratory infection. Some patients have an acute illness that
resembles bacterial pneumonia, in contrast to acute pulmonary
histoplasmosis, which more closely mimics influenza. The onset of
symptoms is abrupt, with high fever and chills, followed by cough that
rapidly becomes productive of large amounts of mucopurulent sputum.
Pleuritic chest pain may occur.
This acute onset is common in an outbreak setting, but also may be seen in
sporadic cases. In most sporadic cases, however, the onset of clinical
symptoms is more gradual. The patient presents with a low-grade fever,
productive cough, and weight loss [48] [51]. Lung cancer or tuberculosis
are highest in the differential diagnosis, rather than bacterial pneumonia,
depending on the roentgenographic findings.
Physical examination is usually unremarkable except for fever.
Auscultation of the chest in patients who have segmental or lobar infiltrates
may show crackles and focal consolidation; more often the physical
examination is negative. Skin lesions are highly variable in appearance,
ranging from subcutaneous nodules and abscesses to papules to ulcers with
heaped up borders mimicking squamous cell cancers. Perhaps the most
characteristic lesion has irregular borders and a crusted surface, varying in
size from 1 to 10 or more centimeters. Skin lesions may be single or
multiple and may occur in crops of several new lesions daily or every few
days if the disease is rapidly disseminating.
Endemic mycosis 207
Routine laboratory tests are seldom helpful. In cases resembling acute
bacterial pneumonia, the white blood cell count is elevated, and frequently
there is a shift to the left toward earlier forms in the granulocyte series.
There is no “characteristic” chest roentgenographic pattern in
blastomycosis [52]. Lesions may vary from single or multiple round
densities throughout both lung fields to segmental or lobar consolidation.
Severe pulmonary infections can present with diffuse infiltrates, nodular,
interstitial, or even alveolar (Figure 3). The diffuse alveolar infiltrates are
identical to acute lung injury (as in acute respiratory distress syndrome) of
diverse cause. Mass-like perihilar infiltrates, especially on the right side,
are common and are often misinterpreted as neoplastic. On the lateral chest
roentgenogram, the mass-like infiltrate is usually behind the hilum, in the
apical-posterior segment of the lower lobe. Hilar lymph node involvement
may occur but is not nearly as common as in histoplasmosis. Cavities may
occur during the acute phase of the illness and usually close during
successful treatment. Unlike histoplasmosis, calcification due to healed
blastomycosis is rare.
Figure 3
47 year old man who failed antibiotic therapy for a community acquired pneumonia, presenting with a rapidly
progressive respiratory failure. Bronchoalveolar lavage recovered Blastomyces dermatitidis.
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Extrapulmonary spread of the fungus may occur during the acute,
symptomatic phase of the illness. In some instances, only the distant lesion
(usually skin or bone) is symptomatic.
The skin and the bony skeleton are the most common sites of symptomatic
extrapulmonary spread. The prostate gland, meninges, oral pharynx,
larynx, and abdominal viscera, including the liver and the adrenal glands,
are involved less frequently [2].
Blastomycosis can present as a progressive infection in patients with T-cell
defects, including organ transplant recipients and other patients being
treated with high-dose glucocorticoids and other immunosuppressive
therapy for malignant and nonmalignant disorders. As with histoplasmosis,
the disease can often be cured with amphotericin B in patients with
intermediate degrees of immunosuppression.
Blastomycosis is much less common in AIDS and other T-cell-deficient
conditions than are histoplasmosis and coccidioidomycosis. This is
probably because exposure to this fungus, while immunosuppressed, is less
common and because there is a smaller reservoir of patients with remote
healed infection waiting to relapse should T-cell function markedly decline
[53].
Blastomycosis can also occur in AIDS, usually with a CD4 count below
Infection is particularly severe, and cure is not likely. Maintenance
therapy is required for those who respond to initial treatment. Patients with
AIDS are likely to progress with widespread dissemination of the infection
with multi-organ involvement. Patients may present with sepsis like
picture. Meningitis or brain abscess are common in this setting and it is
associated with a high early mortality [54].
Diagnosis
The easiest and most rapid method of diagnosis is examination of
expectorated sputum or aspirated pus after 10% potassium hydroxide
digestion [2]. The characteristic large (8- to organism is easily
identified. The yeast is single budding, with a broad neck of attachment
between the parent and the daughter cells. The wall is thick and is double
refractile, and there are multiple nuclei. Other direct fungal stains including
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periodic acid Schiff (PAS), calcoflour white, and silver stains are more
sensitive. Another sensitive technique for rapid diagnosis of blastomycosis
on direct sputum smears is cytologic analysis with the standard
Papanicolaou stain (Figure 4). The direct techniques are probably
complementary and examining multiple sputum samples increases
diagnostic yield [55].
Figure 4
Papanicolaou stain of a sputum specimen from a
patient with rapidly progressive respiratory failure after
a community acquired pneumonia, showing the large
budding yeast with broad neck of blastomyses.
Bronchoscopy is useful when patients are unable to expectorate adequate
sputum, and when urgent diagnosis is needed because of rapid pace of the
illness. In one study, bronchoscopy (specimens obtained included
bronchoalveolar lavage (BAL) in 64% and bronchial washings in all) was
diagnostic in 92% of patients when culture results were included in the
final analysis [56].
For patients who are acutely ill or have an ARDS-like picture, rapid
diagnosis is crucial and can only be achieved by direct examination of
respiratory secretions. If direct sputum smears are negative or not
possible, then bronchoscopy should be done urgently with BAL and
bronchial washings sent for both direct fungal stains (some combination of
KOH, calcofluor white, silver stain, PAS and cytology preparation) and for
culture [57]. The cytology laboratory should be informed whenever there is
high clinical suspicion of infection. Cellblocks of concentrated BAL fluid
can be done to maximize the yield of the submitted specimens.
Histopathologic examination of biopsy material is also an excellent way to
establish the diagnosis. The decision whether or not to perform
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transbronchial biopsies at the time of initial bronchoscopy will likely
depend on contraindications in any given patient that give added risk
beyond risk of BAL. This is particularly true in critically ill patients. If
blastomycosis is being considered in this setting, bronchoscopy with BAL
can be the initial procedure, reserving transbronchial biopsy for cases with
no diagnosis from a safer and easier first procedure. Standard hematoxylin
and eosin stains do not stain the fungus and special stains are required.
The periodic acid-Schiff stain preserves morphological detail, but silver
stains are more commonly used and likely have better sensitivity.
Identification of the fungus by culture is not difficult, but it is slower.
Growth may occur as early as 5 to 7 days but often takes several weeks.
Exoantigen testing can provide positive identification as soon as good
growth is established. Formerly, positive identification required conversion
of the mycelial culture to the yeast phase of growth, adding 1 or more
weeks of delay.
Serologic testing is of limited value in diagnosis of blastomycosis. They are
positive in about a quarter of cases. Most cases of blastomycosis are
diagnosed by smear, culture, and histopathology rather than by serological
tests.
Treatment
Severely ill patients with pulmonary blastomycosis require immediate and
aggressive treatment with amphotericin B.
Itraconazole is highly effective for blastomycosis and is the treatment of
choice for most patients with pulmonary and nonmeningeal disseminated
disease; oral therapy with 400 mg/day for 6 months successfully treats
most patients with mild to moderate pulmonary disease, skin disease, and
bone disease.
Amphotericin B (dosing as described for histoplasmosis; total cumulative
dose 2000 mg) is preferred for a small minority of severely ill patients,
including all patients with diffuse infiltrates and severe gas exchange
abnormalities. Patients with edematous lobar pneumonia (bulging fissures),
extremely toxic patients, and patients who are rapidly disseminating should
all receive AMB. For these severe infections, sequential therapy with AMB
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to clinical improvement (usually 500 to 1000 mg total dose) followed by 6
months of oral itraconazole is often used and is effective though not well
studied. This approach is also used for AIDS patients. Patients with AIDS
and blastomycosis are not permanently cured. Life-long maintenance
therapy is needed after induction therapy to improve symptoms.
Meningeal blastomycosis is always treated with systemic amphotericin B
therapy in standard doses. L- AMB achieves higher brain tissue levels in
animals and may be preferred. Fluconazole is overall less potent for
blastomycocis than itraconazole but penetrates CNS much better. High
dose fluconazole (often in combination with L-AMB) has been used for
central nervous system blastomycosis. Voriconazole is theoretically
attractive but has not been studied. Intracisternal amphotericin B has been
used anecdotally in addition to systemic therapy for selected patients, but it
is uncertain whether there is additional benefit [58], [59] . Intracisternal
therapy is used less often now that there is a wider range of therapy.
COCCIDIOIDOMYCOSIS
Coccidioidomycosis is the illness caused by the tissue-dimorphic fungus
Coccidioides immitis. Although most infections are mild and self-limited,
the spectrum of illness includes life-threatening pulmonary disease and
widely disseminated systemic disease with a high mortality rate.
Differences between it and histoplasmosis and blastomycosis include
different endemic areas, higher frequency of meningeal infections, and
poorer response to all antifungal therapy, including amphotericin B.
Epidemiology
The endemic area for Coccidioidomycosis in North America is the
southwestern United States and the contiguous areas of northern Mexico.
The endemic area of the United States includes central and southern
California and extends eastward to Arizona, New Mexico, and western
Texas.
In nature, the fungus grows as an aerial mycelium with septate hyphae.
Alternating cells form thick-walled barrel-shaped structures called
arthroconidia, with empty cells in between. When a natural site is
212 Tropical and Parasitic Infections in the ICU
disturbed, the mature arthrospores easily detach and become airborne,
producing an infective aerosol.
The risk of infection is greatest during the hot dry summers. Strong winds
can carry the arthrospores for long distances. A huge wind storm that blew
north from the San Joaquin Valley in 1977 caused a major outbreak of
coccidioidomycosis in Sacramento, far north of the usual endemic area
[60]. Not surprisingly, occupations and activities with exposure to the soil
carry the greatest risk for infection, including construction work, farm
labor, and working on archeological digs [61].
Pathogenesis
After inhalation, some arthrospores evade the nonspecific lung defenses
and reach the alveoli, where germination begins. The arthrospores develop
into spherules, the tissue phase of the fungus. Spherules are large, round,
thick-walled structures that vary in diameter between 10 and
Reproduction of the fungus occurs within the spherule. The cytoplasm of
the spherule undergoes progressive cleavage, forming numerous endospores
within the spherule. Once a spherule matures, it bursts and releases the
endospores into the surrounding tissues. Each endospore can become a new
spherule and thus repeat the process.
The initial inflammatory response to inhaled arthrospores is neutrophilic.
Resident alveolar macrophages also phagocytose the arthrospores and
prime specific T lymphocytes, which multiply, recruit more macrophages,
and arm the macrophages, engaging specific cell-mediated immunity. Even
though many well-formed granulomas are seen, the neutrophilic
inflammatory exudate does not disappear. Histopathologically, there is a
mixed granulomatous and suppurative reaction more similar to
blastomycosis than to histoplasmosis [3]. Granuloma formation is
important for successful limitation of the infection. Good outcome
correlates with preponderance of well-formed granulomas.
Most primary infections are asymptomatic or relatively mild. The fungus
usually remains localized to the lung and hilar lymph nodes. Dissemination
occurs in less than 1% of patients. Hematogenous spread can affect many
tissues, including the skin, bones, lymph nodes, visceral organs, and
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meninges [62]. Meningitis is the most feared clinical syndrome with an
ominous prognosis [63].
Clinical Manifestations
Except for rare instances of inoculation coccidioidomycosis, the portal of
entry is the lung. About 60% of individuals with primary pulmonary
infection remain totally asymptomatic. In the remaining 40%, the spectrum
of disease ranges from a mild, influenza-like respiratory illness to a severe,
life-threatening pneumonia [62].
The clinical symptoms and their severity are variable. Common symptoms
include cough, fever, and pleuritic chest pain. Cough may be
nonproductive, or there may be small amounts of mucopurulent sputum.
True rigors are not common. Headache, common during the acute phase of
the illness, is nonspecific. Severe headache is always worrisome, however,
because coccidioidal meningitis often becomes clinically apparent during
the early part of the illness. If meningitis is suspected, a lumbar puncture
should be performed immediately.
Several dermatologic aspects of acute coccidioidomycosis are important. A
mild nonspecific so-called toxic rash occurs in many patients [61], [64]. It
is an erythematous macular rash that occurs early during the illness, before
the skin test turns positive. Erythema nodosum and erythema multiforme
are other skin manifestations of primary coccidioidal infection. Together
with fever and arthralgias, these skin lesions are part of a variable
symptom complex first recognized by locals in the San Joaquin valley of
south central California and labeled “valley fever”.
More than 75% of patients with primary coccidioidomycosis have an
abnormal chest roentgenogram. The most common roentgenographic
abnormality is a single or multiple areas of patchy pneumonitis. The
ipsilateral hilar nodes are enlarged in about 25% of patients [65] . Hilar
adenopathy may also be seen without recognizable parenchymal disease
(Figure 5).
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Figure 5
Acute pulmonary Coccidioidomycosis presenting
as an acute community acquired pneumonia.
This primary complex usually heals rapidly. Necrosis in the center of a
pneumonic lesion may produce cavitation [66]. This is often accompanied
by minor hemoptysis, which may be alarming but is seldom life-
threatening. Hemoptysis as a late complication is uncommon but can be
life-threatening, in contrast to the minimal bleeding that is often seen as the
cavity forms. Another complication is rupture of the cavity with
development of a pyopneumothorax.
In rare instances, primary pulmonary Coccidioidomycosis is not self-limited
but progresses within the lung. Symptoms are fever, cough, and weight
loss. The chest roentgenogram shows progression of the infiltrate and
variable involvement of the hilar nodes[65]. This form of pulmonary
Coccidioidomycosis is dangerous and augers impending dissemination.
Most of the patients with progressive pulmonary disease are either
immunosuppressed or belong to groups at high risk for dissemination.
The primary pulmonary infection usually either resolves completely or
stabilizes. Rarely does a patient die when the disease is restricted to the
lung. In some individuals, however, the fungus spreads widely throughout
the body, resulting in a systemic infection known as disseminated
Coccidioidomycosis.
Patients receiving glucocorticoid or cytotoxic or newer immune modulating
therapy for malignant or nonmalignant diseases are at risk of
dissemination. This is especially true for recipients of renal and other organ
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transplant and patients with AIDS [67], [68]. The excess risk of
coccidiodomycosis in organ transplant recipients in highly endemic areas
has led to targeted prophylaxis to prevent re-activation whenever there is a
history of coccidiodal infection or positive serologic results on pre-
transplant screening [69]. There are other well-recognized risk factors for
dissemination. Race and ethnicity are important. Disseminated
coccidioidomycosis is more likely in blacks, Filipinos, and native
Americans than in whites. Male gender is also a risk factor, as is diabetes
mellitus. The very young and the very old are more likely to have
dissemination[62]. There is much anecdotal information suggesting that
coccidioidomycosis during the third trimester of pregnancy may be a severe
illness with rapid dissemination.
Dissemination from the primary pulmonary focus tends to occur early,
usually within a few months after a symptomatic pulmonary infection. In
some patients, however, the findings of disseminated disease are the first
manifestations of coccidioidomycosis, presumably because the preceding
pulmonary infection was sub-clinical.
Dissemination may involve any organ in the body. The skin is one of the
most common sites of dissemination and is involved in most patients some
time in the course of the disease. Involvement of the bones is the next most
common manifestation of disseminated coccidioidomycosis. Osteomyelitis
may be either the sole evidence of extrapulmonary spread or part of a more
widespread dissemination. Bone disease is usually restricted to one or two
sites, but occasionally as many as eight separate lesions may be present.
Meningitis is the most dreaded complication of coccidioidal dissemination.
Between one third and one half of all patients with disseminated disease
have meningitis, frequently as the only obvious extrapulmonary site. The
onset of meningitis may be subtle, with only mild headache and minimal
alteration of mental functions. Striking boardlike nuchal rigidity, as in
purulent meningitis, is seldom seen [63]. In fact, the findings of meningitis
can be so minimal that all patients with dissemination at other sites should
have a diagnostic lumbar puncture to exclude meningitis. Involvement of
the base of the brain is characteristic. As the disease progresses, an exudate
frequently obstructs the aqueduct of Sylvius and the foramina of the fourth
ventricle, producing hydrocephalus. When obstruction occurs, the patient’s
clinical condition suddenly worsens, with diminished level of consciousness
and the development of papilledema. The cerebrospinal fluid shows
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characteristics of chronic meningitis: predominantly mononuclear cell
pleocytosis, increased protein, and decreased glucose. Occasionally,
eosinophils are present in the cerebrospinal fluid. If present, they are a
valuable clue to the possible coccidioidal nature of the chronic meningitis.
When coccidioidomycosis complicates HIV infection, the severity depends
on the residual immune competence of the host. With near-normal CD4
lymphocyte counts, coccidioidomycosis is not significantly different from
the disease seen in normal hosts. When the CD4 count falls below 250
cells/mL, disseminated disease tends to be severe and rapidly progressive.
Patients usually have high fever, complain of dyspnea, and are hypoxemic;
chest roentgenograms often show diffuse reticulonodular infiltrates with
nodules 5 mm or greater in diameter (Figure 6). Diffuse macronodular
pulmonary infiltrates are present in less than one per cent of non-AIDS
patients with disseminated coccidioidomycosis, but in up to 50% of
advanced AIDS patients with this condition. Meningeal disease is present
in up to 25% of the patients [70], [71] .
Figure 6
Disseminated Coccidioidomycosis in an HTV
infected patient.
Diagnosis
Mycologic Studies. Direct examination of sputum and other respiratory
specimens (or pus from a non-pulmonary site) may reveal the diagnostic
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spherules. Direct smears have highest utility in patients who produce
copious sputum or have multi-lobar infiltrates [72] . Bronchoscopy is often
performed in selected cases. In one study bronchoscopy was diagnostic in
69% of patients (compared to 32% for sputum stains and cultures) when
patients with solitary pulmonary nodules on chest radiograph were
excluded from analysis [73]. This study also showed usefulness of a post-
bronchoscopy sputum and equivalent sensitivity for Papanicolaou and
silver staining. The airway can be examined at the time of bronchoscopy
and may be abnormal, providing clues to the diagnosis [74].
Bronchoscopy is typically performed in patients who are
immunosuppressed and severely ill, especially if they have diffuse
infiltrates on chest radiograph. Multiple infections often co- exist, adding
additional value to diagnostic bronchoscopy early in the course of illness
[75], [76] . Bronchial washings and bronchoalveolar lavage fluid should be
sent for cytology, fungal stains, and culture. In a recent study of an AIDS
patient in Phoenix, Arizona, the Papanicolaou stain was the most useful
direct test (when compared to KOH and calcofluor white) for rapid
diagnosis of pulmonary coccidioidomycosis and was even positive in two
patients with negative cultures [77]. Histopathologic examination of biopsy
material is extremely helpful. When mature spherules (visible on standard
hematoxylin and eosin stained tissue sections) are seen, the diagnosis is
secure. More commonly, only endospores, immature spherules or spherule
fragments are present. Therefore fungal stains such as a silver stain should
always be used in addition to hematoxylin and eosin staining. In one study,
transbronchial biopsy yielded a specific tissue diagnosis of
coccidioidomycosis in eight of eight patients.
Cultural identification of the fungus is not difficult but is hazardous to
laboratory personnel. Isolation should be attempted only under rigid
biohazard protection. Traditional laboratory methods for identifying culture
isolates require conversion of mycelial-phase cultures to the tissue phase
either by animal inoculation or directly by the use of slide cultures. Now
immunodiffusion tests are performed directly on the supernatants of liquid
mycelial-phase cultures. This method of identification (called exoantigen
testing) is safer, simpler, and faster [78]. Positive identification of a
coccidioidal isolate can sometimes be made by day 5, although it usually
takes longer.
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Serologic Studies. Because cultural identification is slow and even
somewhat dangerous, serologic tests have been developed that facilitate
rapid diagnosis [3] [79]. A tube precipitin tests for detection of Ig M
antibodies is positive in 90% of patients by the third week (negative only in
very mild infections). Because the test usually reverts to negative within 3
months, it is quite specific for recent infection[3]. Currently, an
immunodiffusion test for IgM has largely replaced the tube precipitin test.
The immunodiffusion test measures the same antibodies, but it is easier to
perform.
The most important serodiagnostic test is the complement fixation (CF)
test. CF antibodies are of the IgG class and appear later than IgM
antibodies. In most symptomatic patients, the CF test is positive by 2
months and remains positive for several months or longer [79]. The test is
highly specific but is not sensitive. Most asymptomatic skin test converters
never have CF titers over 1:8, which is the threshold for a positive result.
Most symptomatic patients have titers of 1:8 or 1:16. Titers of 1:32 or
higher are generally associated with more severe infections and poorer
prognosis. In the classic studies of Smith and colleagues [79], many
patients with these high titers either had already undergone or were about
to undergo dissemination. However, other patients with disseminated
coccidioidomycosis did not have high titers. Also the cutoff of a 1:32 CF
titer as a harbinger of dissemination never transferred perfectly to other
laboratories that did not use the same method or the same antigen. A single
CF titer, no matter how high, should never be used to make a diagnosis of
disseminated coccidioidomycosis. Nonetheless, a steadily rising titer should
raise the suspicion of disseminated coccidioidomycosis and prompt further
tests (including bone scan, spinal tap, or both when appropriate) to better
define the extent of disease.
Treatment
Because dissemination is more likely in immunosuppressed patients, in
diabetics, and in certain racial and ethnic groups, it may be prudent to treat
patients in high-risk groups during the primary infection, before
dissemination takes place. In the past some authorities recommended a
treatment course to a total dose of 500 to 2000 mg of amphotericin B [80].
Similarly, many experts believed that all patients with pulmonary disease
that is severe or persists beyond a few weeks should receive amphotericin B
to approximately the same total dose to prevent local pulmonary
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progression and to prevent dissemination. In current practice, many such
patients (and also less symptomatic patients with pulmonary
coccidioidomycosis of shorter duration) are often given fluconazole for 3-6
months, reserving AMB for patients with diffuse infiltrates and women in
the third trimester of pregnancy. These recommendations are based on
expert opinion and observational studies.
Amphotericin B is likely the best treatment for persistent pulmonary
coccidioidomycosis. Because of their lesser toxicity, oral azoles are often
tried. About two thirds of patients have clinical improvement with azole
therapy, but many relapse when the course of treatment is finished.
Ketoconazole was used first. Currently fluconazole and itraconazole are
being used. Voriconazole will likely be evaluated in the future.
Disseminated coccidioidomycosis requires prompt and aggressive
treatment. Unfortunately, amphotericin B is not as effective for
disseminated coccidioidomycosis as it is for disseminated histoplasmosis or
blastomycosis. The standard dose of amphotericin B is 2500 to 3000 mg
given over many weeks or months. If necessary, much larger total doses
may be given [81]. Daily doses of amphotericin B (usually 40 to 50 mg)
are given while the patient is acutely ill. When the patient stabilizes,
frequency should be reduced to three times weekly. Currently disseminated
disease without CNS involvement should be treated with fluconazole or
itraconazole first, especially in mild to moderate cases. AMB should be
reserved for severe disease or treatment failure.
Fluconazole and itraconazole are now azoles of choice for nonmeningeal
disseminated coccidioidomycosis. Neither is perfect for difficult cases for
which even amphotericin B is often only suppressive. Long-term therapy is
often required, extending to years or even indefinitely. Fluconazole has the
advantage of better absorption, less gastrointestinal upset, and better
penetration of the central nervous system. In a recently published
randomized controlled trial, oral fluconazole and itraconazole were
compared for treatment of non-meningeal coccidioidomycosis. Soft tissue
dissemination responded best. Overall, itraconazole was somewhat more
effective than fluconazole, producing response in 63% of the patients vs.
50% response in fluconazole treated patients (p = 0.08). Among patients
with skeletal infections, itraconazole was clearly superior, (p=0.05) [82].
Some difficult cases of bone, lymph node, and soft-tissue
coccidioidomycosis may be best managed with surgical drainage of focal
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abscesses, a 1000 to 2000 mg course of amphotericin B, and a prolonged
course of itraconazole or fluconazole.
As might be expected, the treatment of disseminated coccidioidomycosis in
AIDS is particularly difficult. Because of the rapid tempo of the disease,
amphotericin B should be used initially, especially if the patient is severely
ill. If the clinical course stabilizes, it is reasonable to switch to fluconazole
for long-term suppression. Prognosis is poor. Even with prompt diagnosis
and treatment, up to 40% of severely immunosuppressed patients die
during the initial hospitalization. Other patients, usually with lesser degrees
of immunosuppression, respond well to treatment[70], [71] .
Meningeal coccidioidomycosis is a major therapeutic challenge. The
standard therapy in the past included a course of 2000 to 3000 mg systemic
amphotericin therapy plus intensive and lengthy intrathecal (by lumbar or
cisternal route) AMB therapy [63]. Intrathecal (or, less commonly,
intraventricular via surgically placed reservoir [83]) AMB in doses
between 0.25 and 1 mg was injected two to three times weekly until
symptoms and cerebrospinal fluid pleocytosis resolve. Even after the
patient had apparently recovered fully and cerebrospinal fluid pleocytosis
had resolved, most authorities recommended continued injections of
amphotericin to prevent relapse, first weekly and then at longer intervals.
Relapses were common, but, with careful management, lengthy remissions
could be obtained.
Because of the toxicity of this once standard approach to
coccidioidomycotic meningitis, fluconazole has been evaluated as primary
therapy for stable patients and as suppressive therapy after initial response
to amphotericin B for more severely ill patients. Most patients respond
favorably to fluconazole and maintain good clinical function. Dosage is
400 to 600 mg/daily or even higher. Therapy has to be continued long term,
likely indefinitely [84]. Recently anecdotal reports have shown favorable
response to voriconazole and this agent will undoubtedly be tried in various
forms of coccidioidomycosis, including meningitis. A drug with potency
and wide spectrum of itraconazole but with tissue penetration like
fluconazole seems especially attractive for an treatment resistant illness
with high incidence of meningeal spread. However clinical data is sparse.
Severely ill patients with both nonmeningeal and meningeal disease were
previously treated with intravenous and intrathecal amphotericin B. Now
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they are sometimes treated with intravenous amphotericin B for faster,
more effective initial therapy of the nonmeningeal disease and with
fluconazole to control the central nervous system infection. Amphotericin B
is continued to clinical improvement and fluconazole indefinitely.
Newer antifungal agents are being developed; their potential role in
coccidioidomycosis is uncertain. As mentioned voriconazole has some
promise because it has better CNS penetration than itraconazole – and yet
may retain the potency advantage of itraconazole over fluconazole which
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